Gedeon Richter Chief Makes Biosimilars Prophecy
As Company Discusses Sales Prospects For Coming Quarters
Executive Summary
Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.
You may also be interested in...
Gedeon Richter Strikes $16.5m Global Tocilizumab Deal
Gedeon Richter has struck a deal worth $16.5m with Taiwan’s Mycenax for global rights to a tocilizumab biosimilar version of Actemra/RoActemra, setting a date for planned launches in the EU, Japan, Canada and Australia.
EU Suspends Ulipristal Pending Further Review
Gedeon Richter's Esmya should not be prescribed to women while the European Medicines Agency again reviews the risk of serious hepatic injury.
Ulipristal Suspended In EU Pending Further Review
Gedeon Richter's Esmya should not be prescribed to women while the European Medicines Agency again reviews the risk of serious hepatic injury.